TradingKey

關於 BioCryst Pharmaceuticals Inc 公司

BioCryst Pharmaceuticals, Inc. 是一家專注於改善補體介導疾病和其他罕見疾病患者生活的生物技術公司。該公司利用其在設計方面的專業知識開發一流的口服小分子和蛋白質療法，以治療難治疾病。其上市產品包括用於預防遺傳性血管性水腫 (HAE) 發作的口服每日一次 ORLADEYO 和用於治療美國急性無併發症流感的 RAPIVAB（帕拉米韋注射液）。其其他產品和候選產品包括 BCX10013、RAPIACTA（帕拉米韋注射液）、PERAMIFLU（帕拉米韋注射液）和早期發現項目。BCX10013 是一種強效且特異的 D 因子抑制劑。RAPIACTA 專注於無併發症的季節性流感。RAPIVAB（帕拉米韋注射液）在美國獲批用於治療 6 個月及以上患者的急性無併發症流感。

公司簡介

公司代碼BCRX

公司名稱BioCryst Pharmaceuticals Inc

上市日期Mar 04, 1994

CEOMr. Charles K. Gayer

員工數量580

證券類型Ordinary Share

年結日Mar 04

公司地址4505 Emperor Blvd Ste 200

城市DURHAM

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編27703-8457

電話19198591302

網址https://www.biocryst.com/

公司代碼BCRX

上市日期Mar 04, 1994

CEOMr. Charles K. Gayer

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Jon P. Stonehouse

President, Chief Executive Officer, Director

939.88K

-20.60%

Mr. Charles K. Gayer

President, Chief Executive Officer, Director

237.81K

-26.43%

Ms. Alane P. Barnes

Chief Legal Officer, Corporate Secretary

215.03K

-26.71%

Dr. Helen M. Thackray, M.D.

Chief Research & Development Officer

161.62K

-26.06%

Mr. Babar Ghias

Chief Financial Officer, Head of Corporate Development

147.00K

--

Dr. Nancy J. Hutson, Ph.D.

Independent Chairman of the Board

99.14K

+14.43%

Mr. Vincent J. Milano

Independent Director

89.76K

+16.18%

Dr. Steven K. Galson, M.D.

Independent Director

70.87K

+21.41%

Mr. Alan G. Levin

Independent Director

64.27K

+24.14%

Dr. Amy E. Mckee, M.D.

Independent Director

40.33K

+44.91%

名稱

名稱/職務

職務

持股

持股變動

Mr. Jon P. Stonehouse

President, Chief Executive Officer, Director

939.88K

-20.60%

Mr. Charles K. Gayer

President, Chief Executive Officer, Director

237.81K

-26.43%

Ms. Alane P. Barnes

Chief Legal Officer, Corporate Secretary

215.03K

-26.71%

Dr. Helen M. Thackray, M.D.

Chief Research & Development Officer

161.62K

-26.06%

Mr. Babar Ghias

Chief Financial Officer, Head of Corporate Development

147.00K

--

Dr. Nancy J. Hutson, Ph.D.

Independent Chairman of the Board

99.14K

+14.43%

收入明細

暫無數據

暫無數據

業務

地區

暫無數據

股東統計

更新時間: 7月12日週六

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

10.33%

BlackRock Institutional Trust Company, N.A.

8.55%

Kynam Capital Management LP

4.27%

Avoro Capital Advisors LLC

4.16%

State Street Global Advisors (US)

3.73%

Other

68.96%

持股股東

佔比

The Vanguard Group, Inc.

10.33%

BlackRock Institutional Trust Company, N.A.

8.55%

Kynam Capital Management LP

4.27%

Avoro Capital Advisors LLC

4.16%

State Street Global Advisors (US)

3.73%

Other

68.96%

股東類型

持股股東

佔比

Investment Advisor

32.45%

Investment Advisor/Hedge Fund

29.96%

Hedge Fund

18.97%

Research Firm

3.20%

Private Equity

1.84%

Individual Investor

1.27%

Pension Fund

0.53%

Bank and Trust

0.41%

Sovereign Wealth Fund

0.25%

Other

11.14%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

549

185.97M

88.87%

-12.50M

2025Q1

560

182.40M

87.18%

-20.97M

2024Q4

556

172.66M

82.64%

-37.08M

2024Q3

554

179.19M

86.60%

-34.24M

2024Q2

532

180.82M

87.59%

-35.90M

2024Q1

546

187.78M

91.10%

-27.21M

2023Q4

549

183.67M

89.35%

-28.91M

2023Q3

542

183.90M

96.89%

-26.67M

2023Q2

545

181.25M

95.65%

-20.15M

2023Q1

554

177.87M

94.17%

-5.12M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

21.61M

10.33%

-230.66K

-1.06%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

17.89M

8.55%

+189.84K

+1.07%

Mar 31, 2025

Kynam Capital Management LP

8.93M

4.27%

-156.84K

-1.73%

Mar 31, 2025

Avoro Capital Advisors LLC

8.70M

4.16%

-3.17M

-26.68%

Mar 31, 2025

State Street Global Advisors (US)

7.81M

3.73%

+314.44K

+4.19%

Mar 31, 2025

Alkeon Capital Management LLC

6.00M

2.87%

+109.73K

+1.86%

Mar 31, 2025

Two Sigma Investments, LP

5.27M

2.52%

+992.22K

+23.22%

Mar 31, 2025

Deerfield Management Company, L.P.

5.19M

2.48%

-2.95M

-36.28%

Mar 31, 2025

Geode Capital Management, L.L.C.

4.96M

2.37%

+136.90K

+2.84%

Mar 31, 2025

RP Management, LLC

3.85M

1.84%

--

Mar 31, 2025

持股ETF

更新時間: 8月2日週六

機構名稱

佔比

iShares Genomics Immunology and Healthcare ETF

3.3%

Invesco Biotechnology & Genome ETF

2.21%

Invesco Dorsey Wright Healthcare Momentum ETF

1.83%

Virtus LifeSci Biotech Products ETF

1.66%

ALPS Medical Breakthroughs ETF

1.27%

SPDR S&P Biotech ETF

0.68%

First Trust Small Cap Growth AlphaDEX Fund

0.66%

Main Thematic Innovation ETF

0.58%

Direxion Daily S&P Biotech Bull 3X Shares

0.39%

Invesco NASDAQ Future Gen 200 ETF

0.38%

iShares Genomics Immunology and Healthcare ETF

佔比3.3%

Invesco Biotechnology & Genome ETF

佔比2.21%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比1.83%

Virtus LifeSci Biotech Products ETF

佔比1.66%

ALPS Medical Breakthroughs ETF

佔比1.27%

SPDR S&P Biotech ETF

佔比0.68%

First Trust Small Cap Growth AlphaDEX Fund

佔比0.66%

Main Thematic Innovation ETF

佔比0.58%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.39%

Invesco NASDAQ Future Gen 200 ETF

佔比0.38%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

BioCryst Pharmaceuticals Inc

8.685USD

BioCryst Pharmaceuticals Inc

8.685

概覽

公司

財務